1. Modulatory Potential of Poly (ADP‐Ribose) Polymerase 1 (PARP1) in BRCA‐Mutated Tumors
   Valens Munyembaraga et al, 2024, European Journal of Cancer Care CrossRef
2. Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors
   Yaqian Tan et al, 2024, Heliyon CrossRef
3. The dynamic process of covalent and non-covalent PARylation in the maintenance of genome integrity: a focus on PARP inhibitors
   Adèle Beneyton et al, 2023, NAR Cancer CrossRef
4. Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation
   Weiyuan Wang et al, 2024, Cancers CrossRef
5. Histone and DNA Methylation as Epigenetic Regulators of DNA Damage Repair in Gastric Cancer and Emerging Therapeutic Opportunities
   Katia De Marco et al, 2023, Cancers CrossRef
6. Exceptional synergistic response of PARP inhibitor and immune checkpoint inhibitor in esophageal adenocarcinoma with a germline BRCA2 mutation: a case report
   Himil Mahadevia et al, 2024, Therapeutic Advances in Medical Oncology CrossRef
7. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
   Fen Xiao et al, 2024, Journal of Translational Medicine CrossRef